Lanario, Joseph W.
Cartwright, Lucy
Jones, Rupert C.
Sayers, Ross
Hyland, Michael E.
Masoli, Matthew
Funding for this research was provided by:
GlaxoSmithKline (Innovations in Severe Asthma grant)
Article History
Received: 17 May 2022
Accepted: 14 November 2022
First Online: 28 November 2022
Declarations
:
: All participants provided written informed consent and the study was conducted in accordance with the Declaration of Helsinki. This study received sponsor approval from the University of Plymouth and REC/HRA approval from Wales Research Ethics Committee 3 (REC Reference: 21/WA/0147, IRAS ID: 280843).
: Not applicable.
: J.W Lanario reports non-promotional research grants from GSK, AZ and Teva outside the submitted work. L. Cartwright reports a non-promotional research grant from GSK outside the submitted work. R.C. Jones reports non-promotional research grants from GSK, AZ, Teva outside the submitted work and personal fees form GSK, Novartis and Optimum Patient Care. R. Sayers has nothing to report. M.E. Hyland reports non-promotional research grants from GSK, AZ and Teva outside the submitted work and personal fees GSK. M. Masoli reports a non-promotional research grant from GSK outside the submitted work and personal fees from GSK and AZ.